Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Titel:
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Auteur:
Maio, Michele Lewis, Karl Demidov, Lev MandalĂ , Mario Bondarenko, Igor Ascierto, Paolo A Herbert, Christopher Mackiewicz, Andrzej Rutkowski, Piotr Guminski, Alexander Goodman, Grant R Simmons, Brian Ye, Chenglin Yan, Yibing Schadendorf, Dirk